In conclusion, ubiquitination/deubiquitination can regulate the expression of intrinsic and classical PD-L1, thus affecting tumor immunotherapy (including ICB), but its efficacy in vivo and specific mechanism have not been proved yet (Fig. 3B). Here, CD274 is linked to neoplasm.